| Similar Articles |
|---|
 |
The Motley Fool
June 26, 2009
Brian Orelli |
Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.   |
The Motley Fool
February 3, 2011
Brian Orelli |
Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes. |
The Motley Fool
May 11, 2011
Brian Orelli |
Boston Scientific Investors' Parting Gift Less than two years in, Elliot is out. |
The Motley Fool
September 14, 2011
Brian Orelli |
How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. |
The Motley Fool
April 23, 2008
Brian Orelli |
Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up. |
The Motley Fool
February 7, 2006
Stephen D. Simpson |
Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again. |
The Motley Fool
September 29, 2010
Brian Orelli |
Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around. |
The Motley Fool
February 1, 2010
Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
The Motley Fool
February 12, 2010
Brian Orelli |
Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year. |
The Motley Fool
July 23, 2008
Brian Orelli |
Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down. |
The Motley Fool
December 5, 2005
Stephen D. Simpson |
Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note. |
The Motley Fool
April 9, 2010
Brian Orelli |
Is Boston Scientific Turning It Around? Selling off a pair of units could help. |
The Motley Fool
February 5, 2008
Brian Orelli |
Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter. |
The Motley Fool
September 21, 2010
Brian Orelli |
An Acquisition Helps Boston Scientific Breathe Easier Boston Scientific diversifies by picking up device maker Asthmatx. |
The Motley Fool
July 31, 2006
Stephen D. Simpson |
Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself. |
The Motley Fool
October 18, 2010
Anand Chokkavelu |
There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific. |
The Motley Fool
July 21, 2010
Brian Orelli |
Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now. |
The Motley Fool
June 29, 2006
Jim Mueller |
Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition. |
The Motley Fool
December 3, 2010
Seth Jayson |
How Boston Scientific May Be Failing You With recent TTM margins all well below historical averages, Boston Scientific has some work to do. |
The Motley Fool
December 31, 2007
Brian Orelli |
Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed. |
The Motley Fool
January 29, 2009
Brian Orelli |
No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed. |
The Motley Fool
June 24, 2009
Brian Orelli |
Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well. |
The Motley Fool
May 25, 2005
Stephen D. Simpson |
Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors. |
The Motley Fool
October 14, 2005
Stephen D. Simpson |
Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is. |
BusinessWeek
December 6, 2004
Gene G. Marcial |
Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23. |
The Motley Fool
September 26, 2005
Stephen D. Simpson |
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? |
The Motley Fool
October 13, 2008
Brian Orelli |
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. |
The Motley Fool
May 28, 2004
W.D. Crotty |
Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability. |
The Motley Fool
January 11, 2008
Brian Orelli |
Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008. |
The Motley Fool
July 23, 2007
Ryan Fuhrmann |
Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note. |
The Motley Fool
June 13, 2006
Jim Mueller |
Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note. |
The Motley Fool
December 13, 2011
Dan Caplinger |
Has Boston Scientific Become the Perfect Stock? Since we looked at Boston Scientific last year, the maker of medical devices has gotten up off the mat and quadrupled its score. |
The Motley Fool
February 1, 2005
Stephen D. Simpson |
Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth. |
CIO
November 23, 2009
Kim S. Nash |
Innovation: How Boston Scientific Shares Data Securely to Foster Product Development Medical device maker is encouraging innovation through software that breaks down information silos while protecting data. |
The Motley Fool
May 29, 2008
Brian Orelli |
Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific. |
The Motley Fool
April 27, 2010
Brian Orelli |
Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless. |
The Motley Fool
January 6, 2009
Brian Orelli |
Boston Scientific Gets Gussied Up Boston Scientific is buying it's current partner, Ireland-based Labcoat. |
The Motley Fool
August 12, 2010
Brian Orelli |
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. |
The Motley Fool
June 1, 2004
Jeff Hwang |
Expanding Boston Scientific The medical device maker takes advantage of Taxus sales to expand. |
The Motley Fool
May 24, 2006
S.J. Caplan |
Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note. |
The Motley Fool
July 29, 2011
Brian Orelli |
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. |
The Motley Fool
November 11, 2009
Jim Mueller |
This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions. |
The Motley Fool
May 25, 2010
Brian Orelli |
Medtronic Gets Tossed Out With the Bathwater A bad day to report good news. |
The Motley Fool
October 20, 2009
Robert Steyer |
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. |
The Motley Fool
June 22, 2005
Stephen D. Simpson |
Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it. |
The Motley Fool
January 17, 2006
Stephen D. Simpson |
High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this. |
The Motley Fool
April 18, 2006
Stephen D. Simpson |
Get Ready for the New Boston Scientific Here's hoping it does a better job as a bigger business. For all of the risks that are present, there still could be rewards here for investors. |
BusinessWeek
September 22, 2003
Faith Arner |
When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles. |
